
Nephrologist

No OPD information available
Anemia
High Potassium Level
Iron Deficiency Anemia
Autosomal Dominant Polycystic Kidney Disease
Bowen's Disease
Chronic Kidney Disease
Colonoscopy
Colorectal Cancer
Glomerulonephritis
Hypertension
IgA Nephropathy
Kidney Transplant
Low Sodium Level
Polycystic Kidney Disease
Pure Red Cell Aplasia
Simon D. Roger is a male healthcare provider who helps patients with various health issues like anemia, high potassium levels, kidney diseases, cancer, and more. He specializes in treating conditions such as iron deficiency anemia, chronic kidney disease, hypertension, and colorectal cancer.
Simon D. Roger uses special skills and treatments to care for his patients. He performs procedures like colonoscopies and kidney transplants. He is skilled in managing conditions like IgA nephropathy and pure red cell aplasia.
Patients trust Simon D. Roger because he communicates effectively with them. He listens to their concerns, explains treatments clearly, and involves them in decision-making about their health. Patients feel supported and cared for under his guidance.
Simon D. Roger stays updated with the latest medical knowledge and research to provide the best care for his patients. He attends conferences, reads medical journals, and collaborates with other healthcare professionals to enhance his expertise.
In his work, Simon D. Roger collaborates closely with colleagues and other medical professionals. He values teamwork and believes in a multidisciplinary approach to patient care. By working together, they ensure comprehensive and effective treatment for patients.
Simon D. Roger's dedication and expertise have positively impacted many patients' lives. Through his treatments and interventions, he has improved the health outcomes and quality of life for numerous individuals facing complex health challenges.
One of Simon D. Roger's notable publications is a study on treating polyomavirus infection in kidney transplant recipients. He is also involved in a clinical trial investigating the use of Atrasentan in patients with proteinuric glomerular diseases, showing his commitment to advancing medical research and improving patient care.
Enrollment Status: Active not recruiting
Published: January 30, 2025
Intervention Type: Drug
Study Drug: Atrasentan
Study Phase: Phase 2
